Pemetrexed and malignant pleural mesothelioma

Annals of Oncology

Volumn 17, Issue SUPPL. 5, 2006, Pages

  Marangolo, M ^a   Vertogen, B ^a  

^a Dipartimento di Medicina   (Italy)

Author keywords

Chemotherapy; Malignant pleural mesothelioma; Pemetrexed

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; FOLIC ACID; FOLINIC ACID; GEMCITABINE; PEMETREXED; STEROID;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; LUNG SURGERY; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; VITAMIN SUPPLEMENTATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; GLUTAMATES; GUANINE; HUMANS; ITALY; MESOTHELIOMA; PLEURAL NEOPLASMS;

EID: 33745603227     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj962     Document Type: Review

References (15)

1. White C. Annual deaths from Mesothelioma in Britain to reach 2000 by 2010. Br J Med 2003; 326: 1417.
2. International Agency for Research on Cancer. Cancer Epidemiologic Database. www.iarc.fr/ENG/databases.
3. Ball DI, Cruickshank DG. The treatment of malignant Mesothelioma of the pleura: Review of a 5-yr experience with special reference to radiotherapy. Am J Clin Oncol 1990; 13: 4-9.
4. Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural Mesothelioma: A Lung Cancer Study Group trial. J Thorac Cardiovasc. Surg 1991; 102: 1-9.
5. Janne PA, Taffaro ML, Sanglia R, Johnsosn BE. Inhibition of Epidermal Growth Factor Receptor signalling in malignant pleural mesothelioma. Cancer Res 2002; 62: 5242-47.
6. Marrogi A, Pass HI, Khan M et al. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): In vitro antiproliferative effect of a COX-2 inhibitor. Cancer Res 2000; 60: 3696-700.
7. Wang Y, Zhao R, Chattopadhyay S, Goldman ID. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new generation antifolate, Pemetrexed. Cancer Res 2002; 62: 5434-37.
8. Niyikyza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from Pemetrexed therapy. Mol Cancer Ther 2002; 1: 545-52.
9. Scagliotti MV, Shin DM, Kindler HI et al. Phase II study of Pemetrexed with or without folinic acid and vitamin B12 as front-line therapy for malignant pleural Mesothelioma. J Clin Oncol 2003; 21: 1556-1561.
10. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of Pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
11. Hazarika M, White RM, Booth BP et al. Report from the Food and Drug Administration. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 2005; 11: 982-992.
12. Wozniak AJ, Janne P, Belani CP et al. Pemetrexed in combination with cisplatin in the treatment of chemonaive patients with Malignant Pleural Mesothelioma (MPM): Outcomes on Expanded Access Program (EAP). Proc ASCO 2004; Abstr #7192.
13. Orlando M, Wozniak AJ, Janne P et al. Survival update of a subset of previously treated patients with Malignant Pleural Mesothelioma (MPM) in an expanded access program (eap) of Pemetrexed (P) alone or in combination with cisplatin (cis). Proc ASCO 2005; Abstr #7173.
14. Ceresoli GL, Zucali PA, Favaretto A et al. A phase II study of pemetrexed and carboplatin as front-line chemotherapy in patients with malignant pleural mesothelioma. Proc ASCO 2005; Abstr #7172.
15. Janne PA, Simon GR, Langer CJ et al. An update of Pemetrexed (P) plus Gemcitabine (G) as front-line chemotherapy in patients with malignant pleural Mesothelioma. A phase II clinical trial. Proc ASCO 2005; Abstr #7067.